CD19 CAR-Targeted T Cells Induce Long-Term Remission and B Cell Aplasia in an Immunocompetent Mouse Model of B Cell Acute Lymphoblastic Leukemia Journal Article

   

Authors:	Davila, M. L.; Kloss, C. C.; Gunset, G.; Sadelain, M.
Article Title:	CD19 CAR-Targeted T Cells Induce Long-Term Remission and B Cell Aplasia in an Immunocompetent Mouse Model of B Cell Acute Lymphoblastic Leukemia
Abstract:	Although many adults with B cell acute lymphoblastic leukemia (B-ALL) are induced into remission, most will relapse, underscoring the dire need for novel therapies for this disease. We developed murine CD19-specific chimeric antigen receptors (CARs) and an immunocompetent mouse model of B-ALL that recapitulates the disease at genetic, cellular, and pathologic levels. Mouse T cells transduced with an all-murine CD3ζ/CD28-based CAR that is equivalent to the one being used in our clinical trials, eradicate B-ALL in mice and mediate long-term B cell aplasias. In this model, we find that increasing conditioning chemotherapy increases tumor eradication, B cell aplasia, and CAR-modified T cell persistence. Quantification of recipient B lineage cells allowed us to estimate an in vivo effector to endogenous target ratio for B cell aplasia maintenance. In mice exhibiting a dramatic B cell reduction we identified a small population of progenitor B cells in the bone marrow that may serve as a reservoir for long-term CAR-modified T cell stimulation. Lastly, we determine that infusion of CD8+ CAR-modified T cells alone is sufficient to maintain long-term B cell eradication. The mouse model we report here should prove valuable for investigating CAR-based and other therapies for adult B-ALL. © 2013 Davila et al.
Keywords:	signal transduction; cancer chemotherapy; cancer survival; controlled study; unclassified drug; nonhuman; antigens, cd3; cd8-positive t-lymphocytes; animal cell; mouse; animals; mice; animal tissue; mus; gene expression; animal experiment; cyclophosphamide; in vivo study; in vitro study; acute lymphoblastic leukemia; cell lineage; b-lymphocytes; transduction, genetic; disease model; t lymphocyte receptor; cancer regression; receptors, antigen, t-cell; antineoplastic agents, alkylating; murinae; remission induction; chimeric antigen receptor; cell therapy; adoptive transfer; precursor cell lymphoblastic leukemia-lymphoma; immunophenotyping; disease models, animal; drug dose increase; immunotherapy, adoptive; t lymphocyte activation; lymphocyte depletion; cd19 antigen; lymphocyte antigen receptor; antigens, cd19; cd28 antigen; antigens, cd28; immunocompetence; pre b lymphocyte; tumor cell destruction; mutant chimeric proteins; lymphocyte subpopulation; lymphocyte antigen; aplasia; cd3zeta antigen; b cell aplasia; cd19 chimeric antigen receptor targeted t cell therapy; conditioning chemotherapy
Journal Title:	PLoS ONE
Volume:	8
Issue:	4
ISSN:	1932-6203
Publisher:	Public Library of Science
Date Published:	2013-04-09
Start Page:	e61338
Language:	English
PROVIDER:	scopus
PMCID:	PMC3621858
PUBMED:	23585892
DOI:	10.1371/journal.pone.0061338
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-84876050411&partnerID=40&md5=5b293369f50a10b8aecdd73d7d7f7127
Notes:	--- - "Export Date: 1 May 2013" - ":doi 10.1371/journal.pone.0061338" - "Source: Scopus"

https://synapse.mskcc.org/synapse/works/has_related_data_chk/40584